NCT00251368View on ClinicalTrials.gov

Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 31, 1995

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
Leukemia, Myelocytic, AcuteAcute Lymphocytic Leukemia
Interventions
DRUG

9-Aminocamptothecin (9-AC)

Trial Locations (2)

02114

Massachusetts General Hosptial, Boston

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Massachusetts General Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00251368 - Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia | Biotech Hunter | Biotech Hunter